GC Green Cross announced on the 20th that it has released an upgraded version of WAPPS-Hemo, a personalized software for hemophilia patients in Korea.
WAPPS-Hemo is software that helps medical professionals prescribing GC Green Cross's hemophilia treatments, GreenGene F and GreenMono, predict patients' pharmacokinetic profiles to determine appropriate dosing amounts and intervals. It was first launched by GC Green Cross in 2022, the first among domestic pharmaceutical companies in Korea. Patients using WAPPS-Hemo can proactively manage their condition by checking their predicted blood coagulation factor levels through a dedicated mobile application.
With this upgrade, WAPPS-Hemo has improved accuracy in individual prophylactic treatment by utilizing approximately four times more real-world data (RWD) than the previous population pharmacokinetic model. In particular, accuracy has significantly increased for prophylactic treatment in pediatric and elderly patients.
Dr. Yoo Ki-young, director of the Korea Hemophilia Foundation Clinic, stated, “The use of WAPPS-Hemo in clinical settings has reduced the annual bleeding frequency in hemophilia patients and improved their quality of life, while also enhancing understanding of pharmacokinetics-based prophylactic therapy. We expect that this upgrade will enable more precise predictions, greatly aiding personalized treatment for each patient.”
Choi Bong-gyu, head of the Data Science Center at GC Green Cross, also said, “Personalized treatment is expected to improve medication adherence, reduce total medical costs due to decreased bleeding rates, and simultaneously enhance patients’ quality of life. We will continue to make efforts to create an environment where patients with rare diseases can receive optimal treatment tailored to their needs.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
